This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment
Fujiwara, Yoshinori,
Suzuki, Hiroyuki,
Yasunaga, Masashi,
Sugiyama, Mika,
Ijuin, Mutsuo,
Sakuma, Naoko,
Inagaki, Hiroki,
Iwasa, Hajime,
Ura, Chiaki,
Yatomi, Naomi,
Ishii, Kenji,
Tokumaru, Aya M,
Homma, Akira,
Nasreddine, Ziad,
Shinkai, Shoji
Aim: The Montreal Cognitive Assessment (MoCA), developed by Dr Nasreddine (Nasreddine et al. 2005), is a brief cognitive screening tool for detecting older people with mild cognitive impairment (MCI). We examined the reliability and validity of the Japanese version of the MoCA (MoCA-J) in older Japanese subjects.; Methods: Subjects were recruited from the outpatient memory […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Faxén-Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Hjorth, Erik,
Palmblad, Jan,
Vedin, Inger,
Cederholm, Tommy,
Wahlund, Lars-Olof
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]
Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Farokhnia, Mehdi,
Shafiee Sabet, Mehdi,
Iranpour, Negar,
Gougol, Amirhossein,
Yekehtaz, Habibeh,
Alimardani, Roozbeh,
Farsad, Farzaneh,
Kamalipour, Maryam,
Akhondzadeh, Shahin
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]
Effects of cognitive training on gray matter volumes in memory clinic patients with subjective memory impairment
Engvig, Andreas,
Fjell, Anders M.,
Westlye, Lars T.,
Skaane, Nina V.,
Dale, Anders M.,
Holland, Dominic,
Due-Tønnessen, Paulina,
Sundseth, Øyvind,
Walhovd, Kristine B.
Subjective memory impairment (SMI) is a common risk factor for Alzheimer’s disease, with few established options for treatment. Here we investigate the effects of two months episodic memory training on regional brain atrophy in 19 memory clinic patients with SMI. We used a sensitive longitudinal magnetic resonance imaging protocol and compared the patients with 42 […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]
“Learning to become a family caregiver” efficacy of an intervention program for caregivers following diagnosis of dementia in a relative
Ducharme, F. C.,
Levesque, L. L.,
Lachance, L. M.,
Kergoat, M.-J.,
Legault, A. J.,
Beaudet, L. M.,
Zarit, S. H.
Purpose: The purpose of this experimental study was to test the efficacy of a psychoeducational individual program conceived to facilitate transition to the caregiver role following diagnosis of Alzheimer disease in a relative.; Design and Methods: Caregivers were recruited in memory clinics and randomized to an experimental group (n = 62) or a control group […]
A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
Doody, Rachelle S.,
Raman, Rema,
Farlow, Martin,
Iwatsubo, Takeshi,
Vellas, Bruno,
Joffe, Steven,
Kieburtz, Karl,
He, Feng,
Sun, Xiaoying,
Thomas, Ronald G.,
Aisen, Paul S,
Siemers, Eric,
Sethuraman, Gopalan,
Mohs, Richard
Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]